Latin American position on the current status of hormone therapy during the menopausal transition and thereafter

Maturitas

Volumn 55, Issue 1, 2006, Pages 5-13

  Maia Jr , Hugo ^a   Albernaz, Marco Aurélio ^a   Baracat, Edmund Chada ^a   Barbosa, Ione Cristina ^a   Bossemeyer, Ronald ^a   Bueno, Alberto Hernández ^a   Campos, Oscar González ^a   Carranza Lira, Sebastián ^a   Casas, Pedro Figueroa ^a   Castro, Álvaro Monterrosa ^a   de Lima, Geraldo Rodrigues ^a   de Melo, Nilson R ^a   Fernandes, César Eduardo ^a   González, Javier Santos ^a   Larrañaga, Francisco Espinosa ^a   Siseles, Néstor ^a   Uribe, Alfonso Murillo ^a   Vilchez, Rafael Molina ^a  

^a NONE

Author keywords

Consensus; Hormone therapy; Latin America; Menopause; Position statement; WHI study

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PAROXETINE; TIBOLONE; VENLAFAXINE;

ARTICLE; BRAZIL; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSENSUS; DEMENTIA; GALLBLADDER DISEASE; HEART INFARCTION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; OSTEOPOROSIS; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOUTH AND CENTRAL AMERICA; STATISTICAL SIGNIFICANCE; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOUTH AMERICA;

EID: 33746335631     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.03.009     Document Type: Article

References (40)

1. Anonymous. Role of progestogen in hormone therapy of postmenopausal women: position statement of the North American Menopause Society. Menopause 2003; 10: 113-32.
2. Grodstein F., and Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 38 (1995) 199-210
3. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335 (1996) 453-461
4. Anonymous. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004; 11: 589-600.
5. Anonymous. Guidelines for hormone treatment of women in the menopausal transition and beyond. Position statement by the Executive Committee of the International Menopause Society. Climacteric 7 (2004) 8-11
6. Skouby S.O., Al-Azzawi F., Barlow D., et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 51 (2005) 8-14
7. Información y Formación para el Manejo Actual de la Mujer en su Climaterio. In: Siseles N ed. Buenos Aires: Ed. Ascune Hnos, 2005; 562-74 (In press at the time of the panel meeting).
8. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
9. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERSII). JAMA 288 (2002) 49-57
10. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
11. Hodis H.N., Mack W.J., Azen S.P., et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349 (2003) 535-545
12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
13. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
14. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291 (2004) 1701-1712
15. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 166 (2006) 357-365
16. Westhoff C. Risk of pulmonary embolism/venous thrombosis. In: Lobo R.A., Kelsey J., and Marcus R. (Eds). Menopause biology and pathobiology (2000), Academic Press, San Diego 607-615
17. Wassertheil-Smoller S., Hendrix S.L., Limacher M., et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 289 (2003) 2673-2684
18. Simon J.A., Hsia J., Cauley J.A., et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 103 (2001) 638-642
19. Stein J., and Ravnikar V. Postmenopausal compliance with hormone therapy. In: Lobo R.A. (Ed). Treatment of the postmenopausal woman: basic and clinical aspects (1999), Lippincott Williams & Wilkins, Philadelphia 445-451
20. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350 (1997) 1047-1059
21. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
22. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289 (2003) 3243-3253
23. Schneider L.S. Estrogen and dementia. JAMA 291 (2004) 3005-3007
24. Shumaker S.A., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA 291 (2004) 2947-2958
25. Shumaker S.A., Legault C., Rapp S.R., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA 289 (2003) 2651-2662
26. Rapp S.R., Espeland M.A., Shumaker S.A., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. JAMA 289 (2003) 2663-2672
27. Kronenberg F. Hot flashes. In: Lobo R.A. (Ed). Treatment of the postmenopausal woman: basic and clinical aspects (1999), Lippincott Williams & Wilkins, Philadelphia 157-177
28. Bachmann G.A., Ebert G.A., and Burd I.D. Vulvovaginal complaints. In: Lobo R.A. (Ed). Treatment of the postmenopausal woman: basic and clinical aspects (1999), Lippincott Williams & Wilkins, Philadelphia 195-201
29. Wells G., Tugwell P., Shea B., et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23 (2002) 529-539
30. Kanis J.A. Diagnosis of osteoporosis. Osteoporos Int 7 Suppl. 3 (1997) S108-S116
31. Lindsay R., Gallagher J.C., Kleerekoper M., and Pickar J.H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287 (2002) 2668-2676
32. Ettinger B., Ensrud K.E., Wallace R., et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104 (2004) 443-451
33. Nesheim B.I., and Saetre T. Reduction of menopausal hot flushes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol 20 (1981) 413-416
34. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356 (2000) 2059-2063
35. ®) in controlling hot flashes in breast cancer survivors. Ann Oncol 11 (2000) 17-22
36. Loprinzi C.L., Barton D.L., Sloan J.A., et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 77 (2002) 1159-1163
37. Basavilvazo M.A., Bravo-Rodriguez L.M., Carranza-Lira S., et al. Primer consenso nacional multidisciplinario sobre terapia de reemplazo hormonal. Rev del Clim 7 (2004) 156-179
38. Fernandes CE, Soares-Pereira A, Bonassi-Machado R, et al. Consenso da SOBRAC-Associação Brasileira de Climatério. Terapeutica hormonal na peri e na pós-menopausa. Cap. 7. Ed. Medcomm, 2004. São Paulo, Brasil.
39. Campodónico I, Siseles N, Gutierrez P, et al. Consenso Latinoamericano sobre terapia hormonal postmenopausica (Memoria Mecanógrama). Salta, Argentina 14-15 de agosto de 2003. On file.
40. Salkind N.J. Exploring research. 4th ed. (2000), Prentice Hall, Upper Saddle River, NJ p. 132-133